# Kerry account plan

> Kerry Group is an Irish B2B taste and nutrition ingredients company for food, beverage and pharma: €6,758m FY2025 revenue, 19,000+ employees.

## At a glance

Kerry Group is a B2B taste and nutrition ingredients company that co-creates products with food, beverage and pharma customers in retail and foodservice, using taste technologies (natural extracts, Tastesense™ salt and sugar reduction, flavours) and biotechnology (fermentation, enzymes, probiotics, proteins). Since selling Kerry Dairy Ireland at the end of 2024 it describes itself as a pure-play taste and nutrition company, sizing its addressable market at c. €85bn. FY2025 revenue from continuing operations was €6,758m (-2.5% reported, volume +3.0%), EBITDA €1,208m at a 17.9% margin, and free cash flow €643m. It has 19,000+ employees and 119 manufacturing facilities in 34 countries. Edmond Scanlon has been CEO since October 2017.

## Business units

- **Americas** (€3,674m FY2025 revenue): The largest region, with FY2025 volume growth of 3.8% led by Snacks, Dairy and Bakery and strong growth in foodservice with quick service and fast casual restaurants; revenues in the USA alone were €2,840.0m. In H1 2026 revenue was €1,818m at an 18.9% EBITDA margin, and nine-month 2026 volume grew 4.0%, with LATAM led by Mexico.
- **APMEA** (€1,644m FY2025 revenue): Asia Pacific, Middle East and Africa: FY2025 volume grew 4.2%, led by Southeast Asia, Bakery, Meat and Meals, while China was challenged. Kerry opened its first plant in Egypt and a facility in Rwanda; H1 2026 revenue was €831m at a 15.8% margin and nine-month volume grew 5.2% with China returning to growth.
- **Europe** (€1,440m FY2025 revenue): Volume fell 0.5% in FY2025 on subdued retail markets, while Beverage and Snacks did well and EBITDA margin expanded 90bps. H1 2026 revenue was €687m at a 16.0% margin; nine-month volume grew 0.7%, led by low / no alcohol beverages, snacks and dairy.

## Strategic priorities

- **2030 financial targets**: Announced in July 2026: volume growth of 3-5% on average over 2027-2030 assuming flat end markets, EBITDA margin of 20-21% by 2030, HSD+ constant currency EPS growth, 85%+ cash conversion and 12-13% ROACE by 2030.
- **Accelerate 2.0 efficiency programme**: Runs until 2028, covering footprint optimisation in North America and Europe and digital excellence in manufacturing, commercial enablement and global business service centres; it is the primary driver of margin expansion in FY 2026 and FY 2027.
- **Renovation, foodservice and emerging markets**: Renovation is around 40% of the pipeline and more than half in North America; foodservice volume grew 5.0% and emerging markets 4.9% in the first nine months of 2026.
- **Biotechnology innovation**: Kerry is accelerating biotechnology R&D in next-generation modulation, biotransformation to replace additives and natural preservation; R&D spend is set to rise from 4%-5% to 5%-6% of revenue.
- **Digital and AI at scale**: After piloting, Kerry is scaling digital and AI initiatives across commercial, R&D, supply chain, manufacturing and business functions.

## Latest results

In H1 2026 revenue was €3,336.4m, down 3.7% reported, with volume growth of 3.3%, pricing of -1.0% from input cost deflation and adverse translation currency of 4.8% from the weaker US$. EBITDA was €558.1m at a 16.7% margin (+60bps) and adjusted EPS rose 7.9% in constant currency to 214.1c. The Q3 2026 statement reported nine-month volume growth of 3.6%, stepping up to 4.1% in Q3, with pricing turning positive (+0.2%) and EBITDA margin up 50bps year to date. Kerry maintains FY2026 guidance of 6% to 10% constant currency adjusted EPS growth.

## Investments and deals

- **Capacity and innovation centres**: €301m of capex in 2025, including a Biotechnology Centre in Leipzig, enzyme capacity in Cork, coffee extraction in Pennsylvania and customer innovation centres in Dubai, South Jakarta and Frankfurt; 2026 investments include beverage taste capacity in North America, savoury taste in Mexico, proactive health in Spain and a taste footprint in Türkiye.
- **Bolt-on M&A**: Bolt-ons of EUR 100 million-EUR 200 million per year in emerging markets and biotechnology (biotics and bioactives, enzymes, food protection and preservation).
- **Share buybacks**: €500m of shares repurchased in 2025 and €172.9 million in H1 2026, with a further buyback of up to €300 million planned after the current programme.

## Challenges and risks

- **Currency translation**: The weaker US$ cut reported revenue by 4.8% in H1 2026 and is a 1-2% headwind to FY2026 EPS.
- **Weak European markets**: Europe volumes fell 0.5% in FY2025, with Meals and Bakery still challenged in 2026.
- **Input cost inflation**: The CFO expects 2027 to be inflationary, with dairy-based ingredients, some spices and natural oils rising, after deflation in H1 2026.
- **Geopolitical and macro uncertainty**: Principal risks include trade wars, tariffs, currency volatility and consumer affordability challenges; China volumes were challenged in 2025.

## What leadership says

> "We see this as a structural market shift, it's primarily driven by actually increased consumer expectations." — Edmond Scanlon, Chief Executive Officer, On renovation, H1 2026 results and 2030 targets call, 29 July 2026

> "We are accelerating our investment in biotechnology innovation and very much doubling down" — Edmond Scanlon, Chief Executive Officer, Q3 2026 results call, 22 October 2026

> "Having piloted and proven several initiatives across the organization, we are now scaling across commercial, R&D, supply chain, manufacturing, and business functions." — Edmond Scanlon, Chief Executive Officer, On digital and AI, Q3 2026 results call, 22 October 2026

> "we currently expect 2027 to be an inflationary year" — Marguerite Larkin, Chief Financial Officer, Q3 2026 results call, 22 October 2026


## Where a supplier can help

- **Digital and AI rollout**: Tied to the digital and AI priority and Accelerate 2.0's digital excellence workstream: Kerry is scaling AI across commercial, R&D, supply chain and manufacturing.
- **Footprint optimisation**: Tied to Accelerate 2.0: plant consolidation in North America and Europe creates demand for automation, engineering and transition services.
- **Biotech R&D tooling**: Tied to the biotechnology innovation priority and the rise of R&D spend to 5%-6% of revenue: lab equipment, fermentation and data tools.
- **Procurement and cost management**: Tied to the input cost inflation challenge: sourcing analytics and hedging support for dairy, spices and natural oils.
- **Emerging-market expansion**: Tied to new facilities in Egypt, Rwanda, Türkiye and the Middle East: construction, logistics and local distribution partners.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Kerry Group Annual Report 2025](https://www.kerry.com/content/dam/kerry/en/pdf/investors/results-presentations/2026/kerry-group-annual-report-2025.pdf)

Annual report · 2026-03-19

- Kerry Group is a B2B taste and nutrition ingredients company, now described as a "pure-play taste and nutrition company" after selling Kerry Dairy Ireland (31 December 2024); it serves food, beverage and pharma customers across retail and foodservice, an addressable market of c. €85bn.
- FY2025 (continuing operations): revenue €6,758m (2024: €6,929m, -2.5% reported) with volume growth of 3.0%, pricing -0.3%, translation currency -3.9% and disposals net of acquisitions -1.4%.
- EBITDA €1,208m, margin 17.9% (+80bps), driven by the Accelerate programmes, portfolio developments, operating leverage and mix; constant currency adjusted EPS 481.5c (+7.5%); basic EPS 400.2c (-5.7%).
- Three reportable regions from 1 January 2025: Americas €3,674m revenue (volume +3.8%), APMEA €1,644m (+4.2%), Europe €1,440m (-0.5%); foodservice volume +4.6% and emerging markets volume +5.3%.
- Scale: 19,000+ employees, 119 manufacturing facilities in 34 countries, 60+ technology and innovation centres, 1,200+ R&D scientists and €314m R&D spend.
- Accelerate Operational Excellence completed in 2025; Accelerate 2.0 (footprint optimisation and digital excellence) runs until 2028 and underpins the 19-20% EBITDA margin target by 2028.
- Capital allocation: €301m capex, €215m dividends, €500m of share buybacks in 2025; total dividend 140.0c (+10.1%); free cash flow €643m (81% conversion); net debt €2,244m (1.9x EBITDA).
- Leadership changes: Chair Tom Moran retires at the 2026 AGM with Fiona Dawson taking over; Gerry Behan (President & CEO Kerry Taste & Nutrition) retired 31 December 2025; CEO Edmond Scanlon and CFO Marguerite Larkin continue.

### [Kerry Group Half Year Results 2026 (Interim Management Report)](https://www.kerry.com/content/dam/kerry/en/pdf/investors/results-presentations/2026/kerry-group-interim-management-report-2026.pdf)

Interim report · 2026-07-29

- H1 2026 (published 29 July 2026): revenue €3,336.4m (-3.7% reported) with volume growth of 3.3% (Q2: +3.5%), pricing -1.0% reflecting input cost deflation and adverse translation currency of 4.8% from the weaker US$.
- EBITDA €558.1m, margin 16.7% (+60bps), primarily driven by Accelerate 2.0; adjusted EPS 214.1c, +7.9% in constant currency and +2.3% reported.
- Americas: revenue €1,818m, volume +3.7%, margin 18.9%; Europe: €687m, +0.5%, 16.0%; APMEA: €831m, +4.9%, 15.8%.
- Foodservice volume +4.8% and emerging markets +5.0%; growth led by Snacks, Meat, Dairy and Beverage.
- New 2030 targets: volume growth 3-5% (assuming flat end markets), EBITDA margin 20-21% by 2030, HSD+ constant currency EPS growth, 85%+ cash conversion and 12-13% ROACE by 2030.
- Free cash flow €262.3m (76% conversion); net debt €2,369.8m (2.0x EBITDA); interim dividend 46.2c (+10.0%); €172.9m of shares bought back.
- FY2026 guidance of 6% to 10% constant currency adjusted EPS growth maintained; FX translation a 1-2% EPS headwind.

### [Kerry Group Q3 Interim Management Statement 2026](https://www.kerry.com/content/dam/kerry/en/pdf/investors/results-presentations/2026/q3-2026-results-press-release.pdf)

Interim report · 2026-10-22

- Q3 2026 interim management statement (22 October 2026): year-to-date volume growth of 3.6%, stepping up to 4.1% in Q3, "well ahead of end market growth".
- Pricing -0.6% year to date but +0.2% in Q3, with deflation in H1 turning to inflation; reported revenue down 0.6% year to date after -2.5% translation currency.
- EBITDA margin expanded 50bps, primarily from Accelerate 2.0, while reflecting increased investment in R&D.
- Regions year to date: Americas volume +4.0% (Q3: +4.6%, LATAM led by Mexico), Europe +0.7% (Q3: +1.3%), APMEA +5.2% (Q3: +5.7%).
- Foodservice volume +5.0%; emerging markets +4.9%; Pharma & Other led by excipients.
- Net debt €2.4 billion; intention to launch a further share buyback of up to €300 million after the current programme.
- FY2026 constant currency adjusted EPS growth guidance of 6% to 10% maintained; translation currency ~1% EPS headwind.

### [Kerry Group H1 2026 Results and 2030 Targets Q&A Call (transcript)](https://www.investing.com/news/transcripts/earnings-call-transcript-kerry-group-lifts-volume-outlook-in-strong-h1-2026-93CH-4818879)

Executive talk · Edmond Scanlon, Chief Executive Officer · 2026-07-29

- H1 2026 results and 2030 targets Q&A call (29 July 2026) with CEO Edmond Scanlon and CFO Marguerite Larkin.
- Scanlon raised the FY2026 volume expectation to close to 3.5% (from 3%), with H2 like Q2, while keeping 6%-10% constant currency EPS guidance.
- 2030 volume target of 3%-5% by region: Americas 3%-5%, Europe around 1%-2%, APMEA 5%-9%; growth drivers are foodservice (mid-single-digit plus), emerging markets and renovation.
- Renovation is around 40% of the pipeline, about 60% in North America; Scanlon calls it "a structural market shift" and front-of-pack labelling in the US "a matter of when, not if".
- Kerry says its foodservice market share is "only still at the low teens"; foodservice business grown by 70% since 2017.
- Larkin: margin target of 20%-21% by 2030 from efficiencies (Accelerate) first, then leverage and mix; R&D spend to rise from 4%-5% to 5%-6%; capex stays 4%-5%; cash conversion target raised to 85% plus.
- M&A: bolt-ons of EUR 100 million-EUR 200 million per year in emerging markets and biotechnology (biotics and bioactives, enzymes, food protection and preservation).

### [Kerry Group Q3 2026 Results Call (transcript)](https://www.investing.com/news/transcripts/earnings-call-transcript-kerry-group-posts-strong-q3-2026-growth-stock-steady-93CH-4964858)

Executive talk · Edmond Scanlon, Chief Executive Officer · 2026-10-22

- Q3 2026 results call (22 October 2026) with CEO Edmond Scanlon and CFO Marguerite Larkin.
- Q3 volume growth of 4.1% (nine months 3.6%); Scanlon expects Q4 "similar to Q3" and sees no notable change in consumer demand.
- Margin: 200 basis points of expansion over the past two years and a further 50 basis points expected in 2026; Larkin says Accelerate 2.0 footprint optimisation is "a little bit ahead of plan" and 2027 will be "another year of good margin expansion".
- Kerry is "doubling down" on biotechnology R&D: next-generation modulation, biotransformation to replace additives, natural preservation.
- Investor Day in Beloit, Wisconsin: five next-generation innovation areas each with a potential opportunity "over EUR 50 million"; digital and AI now scaling across commercial, R&D, supply chain and manufacturing.
- Renovation: "more than half the pipeline in North America"; around 80% of the North American snack category still has salt above WHO guidelines; meals reformulation is a 2027+ opportunity.
- Larkin expects 2027 to be inflationary (dairy-based ingredients, spices, natural oils); new buyback of up to EUR 300 million; bolt-on M&A remains active.

## Questions about Kerry

### What does Kerry Group do?

Kerry Group provides taste and nutrition ingredient solutions to food, beverage and pharma companies, co-creating products with customers in retail and foodservice.

### What is Kerry Group's revenue?

FY2025 revenue from continuing operations was €6,758m with EBITDA of €1,208m. H1 2026 revenue was €3,336.4m.

### How many employees does Kerry Group have?

19,000+ employees in 185+ locations and 50+ countries, with 119 manufacturing facilities in 34 countries.

### Who leads Kerry Group?

Edmond Scanlon is CEO and Marguerite Larkin is CFO; the annual report names Fiona Dawson to take over from Tom Moran as Board Chair at the 2026 AGM.

### What are Kerry Group's 2030 targets?

Volume growth of 3-5% a year, an EBITDA margin of 20-21% by 2030, HSD+ constant currency EPS growth, 85%+ cash conversion and 12-13% ROACE.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
